The NRG Oncology Podcast

We discuss the reported results of the NRG-HN009 p16-negative cohort presented at the ASTRO Annual Meeting Late-Breaking Abstract Session.

We discuss both the NRG-CC009 study results presented during the 2026 ASTRO Annual Meeting Plenary Session and the MAVERICK study results presented during the Clinical Trials Session.

We discuss the NRG-GI003 results presented during the 2026 ASTRO Annual Meeting Plenary Session.

We interview Dr. Shang "George" Zhao on the NRG-RTOG 0534 "SPPORT" study results he presented at the 2026 ASTRO Annual Meeting Clinical Trials Session.

For the 2026 Ovarian Cancer Month & Gynecologic Cancer Month, we discuss the currently enrolling NRG-GY036 clinical trial comparing 1 vs. 2 years of maintenance olaparib (with or without bevacizumab) for patients with advanced ovarian cancer with Dr. Liu.

Our co-hosts interview the PI of the active NRG-HN016 (CONCISE) trial, Dr. Loren Mell. The CONCISE study is a randomized phase III trial comparing radiation therapy (RT) plus carboplatin/paclitaxel vs. RT plus cetuximab for patients with locoregionally advanced head and neck cancer who have a contraindication to cisplatin. CONCISE is the first trial comparing the two most commonly used regimens for this population, and the first “pragmatic” trial for solid tumors to be conducted by NRG Oncology.

Our co-hosts welcome Dr. Scott Delacroix and Dr. Himanshu Nagar to discuss bladder cancer, bladder preservation, and the newly activated NRG-GU015 (ARCHER) clinical trial. In this episode, the experts explore who may benefit from bladder-sparing chemoradiation, dispel common misconceptions about organ preservation, and explain how GU015 is evaluating a shorter, adaptive radiation treatment approach that could make curative therapy more accessible for patients with muscle-invasive bladder cancer. They also discuss the importance of multidisciplinary care, patient-centered decision-making, and how innovations in radiation therapy and systemic treatments are shaping the future of bladder cancer care. Whether you're a clinician, researcher, or simply interested in advances in oncology, this episode offers valuable insights into a trial designed to improve both outcomes and quality of life for patients.

For Glioblastoma Awareness Day we discuss the NRG-CC017 study of TMPRT + Temozolomide for glioblastoma with PI, Dr. Huang. We also discuss the challenges faced by larger institutions with Dr. Abraham.

This special Uterine Cancer Month episode includes three different perspectives in Uterine Cancer research. First we interview uterine and ovarian cancer survivor, NRG PAC Member, and Uterine Corpus Subcommittee Patient Advocate, Anna Wilson. Second we look at the recently activated NRG-GY035 clinical study with PI Dr. Amanda Fader. Lastly we discuss uterine cancer research within NRG with Gynecologic Cancer Committee Chair, Dr. Carol Aghajanian.

In this episode, we discuss the results of the combined analysis of the prostate cancer studies RTOG 9202, 9413, 9902, and 0521 as well as learn more about translational science at NRG.